# The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs

> **NCT00002391** · PHASE3 · COMPLETED · sponsor: **Glaxo Wellcome**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Abacavir sulfate
- **DRUG:** Lamivudine
- **DRUG:** Zidovudine

## Key facts

- **NCT ID:** NCT00002391
- **Lead sponsor:** Glaxo Wellcome
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002391, "The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00002391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*